Lactic-acid-bacteria-containing composition, oral pharmaceutical composition for treating HPV infection and/or HPV-associated tumors, and mucosal immunity-inducing agent
AssigneesThe University of Tokyo, Japan Health Sciences Foundation
InventorsKei Kawana, Shizunobu Igimi
Life of this patent
Estimating the term…
Abstract
A lactic acid bacterium-containing composition including a lactic acid bacterium having a human papillomavirus (HPV) E7 protein-derived polypeptide on a surface thereof, wherein the HPV E7 protein-derived polypeptide is included in an amount of 0.03 μg to 1.0 μg per 1×108 lactic acid bacteria; a therapeutic oral pharmaceutical composition for at least one of an HPV infectious disease and an HPV-associated tumor which includes the lactic acid bacterium-containing composition; and a mucosal immunity-inducing agent which includes the lactic acid bacterium-containing composition.
Claims21
A lactic acid bacterium-containing composition comprising
- a lactic acid bacterium having a human papillomavirus (HPV) E7 protein-derived polypeptide on a surface thereof,
- wherein the HPV E7 protein-derived polypeptide is fused with an anchor protein cA derived from AcmA to form a fusion protein or is expressed from a sequence of a nucleic acid coding for the HPV E7 protein-derived polypeptide linked to an anchor gene prtP,
- wherein the HPV E7 protein-derived polypeptide is included in an amount of 0.03 μg to 1.0 μg per 1×108 lactic acid bacteria on the surface of the bacterium.
A therapeutic oral pharmaceutical composition for at least one of an HPV infectious disease and an HPV-associated tumor, the composition comprising
- a lactic acid bacterium-containing composition comprising a lactic acid bacterium having a human papillomavirus (HPV) E7 protein-derived polypeptide on a surface thereof,
- wherein the HPV E7 protein-derived polypeptide is fused with an anchor protein cA derived from AcmA to form a fusion protein, or is expressed from a sequence of a nucleic acid coding for the HPV E7 protein-derived polypeptide linked to an anchor gene prtP,
- wherein the HPV E7 protein-derived polypeptide is included in an amount of 0.03 μg to 1.0 μg per 1×108 lactic acid bacteria on the surface of the bacterium.
A mucosal immunity-inducing agent comprising
- a lactic acid bacterium-containing composition comprising a lactic acid bacterium having a human papillomavirus (HPV) E7 protein-derived polypeptide on a surface thereof,
- wherein the HPV E7 protein-derived polypeptide is fused with an anchor protein cA derived from AcmA to form a fusion protein, or is expressed from a sequence of a nucleic acid coding for the HPV E7 protein-derived polypeptide linked to an anchor gene prtP,
- wherein the HPV E7 protein-derived polypeptide is included in an amount of 0.03 μg to 1.0 μg per 1×108 lactic acid bacteria on the surface of the bacterium.
Dependencies are inferred from the claim text.